These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17712821)

  • 21. From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis.
    Mechoulam R; Ben-Shabat S
    Nat Prod Rep; 1999 Apr; 16(2):131-43. PubMed ID: 10331283
    [No Abstract]   [Full Text] [Related]  

  • 22. Endocannabinoids as regulators of transient receptor potential (TRP) channels: A further opportunity to develop new endocannabinoid-based therapeutic drugs.
    Di Marzo V; De Petrocellis L
    Curr Med Chem; 2010; 17(14):1430-49. PubMed ID: 20166923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The elmiric acids: biologically active anandamide analogs.
    Burstein S
    Neuropharmacology; 2008 Dec; 55(8):1259-64. PubMed ID: 18187165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of endocannabinoids, their congeners and COX-2 metabolites.
    Kingsley PJ; Marnett LJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Sep; 877(26):2746-54. PubMed ID: 19505857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel cannabinoid receptor ligands from diverse marine organisms.
    Soderstrom K; Murray TF; Yoo HD; Ketchum S; Milligan K; Gerwick W; Ortega MJ; Salva J
    Adv Exp Med Biol; 1997; 433():73-7. PubMed ID: 9561107
    [No Abstract]   [Full Text] [Related]  

  • 26. FAAH and anandamide: is 2-AG really the odd one out?
    Di Marzo V; Maccarrone M
    Trends Pharmacol Sci; 2008 May; 29(5):229-33. PubMed ID: 18394720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular transport of anandamide, 2-arachidonoylglycerol and palmitoylethanolamide--targets for drug development?
    Fowler CJ; Jacobsson SO
    Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):193-200. PubMed ID: 12052035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular dynamics simulations of the endocannabinoid N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics.
    Lynch DL; Reggio PH
    J Med Chem; 2005 Jul; 48(15):4824-33. PubMed ID: 16033262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nuclear magnetic resonance for studying recognition processes between anandamide and cannabinoid receptors.
    Bonechi C; Martini S; Brizzi V; Brizzi A; Massarelli P; Bruni G; Rossi C
    Eur J Med Chem; 2006 Oct; 41(10):1117-23. PubMed ID: 16837109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An optimized GC-MS method detects nanomolar amounts of anandamide in mouse brain.
    Muccioli GG; Stella N
    Anal Biochem; 2008 Feb; 373(2):220-8. PubMed ID: 17981259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preferred conformations of endogenous cannabinoid ligand anandamide.
    Chen JZ; Han XW; Xie XQ
    Life Sci; 2005 Mar; 76(18):2053-69. PubMed ID: 15826873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex.
    Steffens M; Feuerstein TJ; van Velthoven V; Schnierle P; Knörle R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Nov; 368(5):432-6. PubMed ID: 14566450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon.
    Smid SD; Bjorklund CK; Svensson KM; Heigis S; Revesz A
    Eur J Pharmacol; 2007 Dec; 575(1-3):168-76. PubMed ID: 17706636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous cannabinoids revisited: a biochemistry perspective.
    Fonseca BM; Costa MA; Almada M; Correia-da-Silva G; Teixeira NA
    Prostaglandins Other Lipid Mediat; 2013; 102-103():13-30. PubMed ID: 23474290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plant cannabinoids: a neglected pharmacological treasure trove.
    Mechoulam R
    Br J Pharmacol; 2005 Dec; 146(7):913-5. PubMed ID: 16205721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide.
    Basta PV; Adcock AF; Tallent CR; Fleming DN; Seltzman HH; Whisnant CC; Cook CE
    J Immunol Methods; 2004 Feb; 285(2):181-95. PubMed ID: 14980433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
    Lambert DM; Fowler CJ
    J Med Chem; 2005 Aug; 48(16):5059-87. PubMed ID: 16078824
    [No Abstract]   [Full Text] [Related]  

  • 39. Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration.
    Matias I; Wang JW; Moriello AS; Nieves A; Woodward DF; Di Marzo V
    Prostaglandins Leukot Essent Fatty Acids; 2006 Dec; 75(6):413-8. PubMed ID: 17011761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and synthesis of (13S)-methyl-substituted arachidonic acid analogues: templates for novel endocannabinoids.
    Papahatjis DP; Nahmias VR; Nikas SP; Schimpgen M; Makriyannis A
    Chemistry; 2010 Apr; 16(13):4091-9. PubMed ID: 20187040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.